Literature DB >> 11270928

Olanzapine and Huntington's disease.

G Bogelman, S Hirschmann, I Modai.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11270928     DOI: 10.1097/00004714-200104000-00023

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  11 in total

1.  Quetiapine in Huntington's disease: a first case report.

Authors:  Raphael M Bonelli; Gerald Niederwieser
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

2.  Treatment of huntington disease.

Authors:  Aleksandar Videnovic
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

3.  Gait and Balance Dysfunction in Adults.

Authors:  Salil Manek; Mark F. Lew
Journal:  Curr Treat Options Neurol       Date:  2003-03       Impact factor: 3.598

Review 4.  An overview of psychiatric symptoms in Huntington's disease.

Authors:  K E Anderson; K S Marder
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

Review 5.  Symptomatic treatment of Huntington disease.

Authors:  Octavian R Adam; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

6.  Treatment of Irritability in Huntington's Disease.

Authors:  Erik van Duijn
Journal:  Curr Treat Options Neurol       Date:  2010-07-10       Impact factor: 3.598

7.  State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.

Authors:  Jessie S Gibson; Daniel O Claassen
Journal:  Expert Opin Pharmacother       Date:  2021-02-08       Impact factor: 4.103

Review 8.  Cell Therapy Strategies vs. Paracrine Effect in Huntington's Disease.

Authors:  Wooseok Im; Manho Kim
Journal:  J Mov Disord       Date:  2014-04-30

Review 9.  Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.

Authors:  Emma M Coppen; Raymund A C Roos
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

10.  Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington's disease (Enroll-HD).

Authors:  Kate L Harris; Wei-Li Kuan; Sarah L Mason; Roger A Barker
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-03-30       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.